Evidence in the treatment of dyslipidemia in the metabolic syndrome

Li Chin Sung, Ji Hung Wang

研究成果: 雜誌貢獻回顧型文獻同行評審

摘要

The metabolic syndrome is a cluster of cardiovascular risk factors as characteristic and correlated with cardiovascular disease and the development of the diabetes mellitus. The characters of dyslipidemia are the hypertriglyceridemia, low high-density lipoprotein cholesterol and small dense low-density lipoprotein cholesterol. As to the patient having a cardiovascular disease (such as coronary artery disease, stroke, or peripheral artery occlusion) or the diabetes mellitus, the 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III suggests reducing the serum low-density lipoprotein cholesterol with statin. However, there remains a relatively high residual risk of morbidity or mortality in patients with the metabolic syndrome or diabetes mellitus, and this is of growing importance because of the increasing prevalence of obesity and its associated comorbidities in the world. The treatment to achieve aggressive goals is of paramount importance. This article reviews pathophysiology and emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.
原文英語
頁(從 - 到)305-317
頁數13
期刊Journal of Internal Medicine of Taiwan
19
發行號4
出版狀態已發佈 - 八月 2008
對外發佈

ASJC Scopus subject areas

  • 內科學

指紋

深入研究「Evidence in the treatment of dyslipidemia in the metabolic syndrome」主題。共同形成了獨特的指紋。

引用此